Replies to post #119 on Sucampo Pharmaceuticals, Inc. (SCMP)

[surf1944]

1:40AM Sucampo Pharma receives $10 mln milestone payment from Takeda (TKPPY) for first sale of AMITIZA for OIC in the US (SCMP) 6.52 : Sucampo Pharmaceuticals announces that it has received a $10 mln milestone payment from Takeda Pharmaceutical (TKPPY). The milestone payment was triggered by the commercial launch of AMITIZA (24 mcg daily) in the United States for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain. The effectiveness of AMITIZA in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids has not been established.